Tetsuya Okazaki1, Megumi Murata2, Masachika Kai3, Kaori Adachi2, Naoko Nakagawa4, Noriko Kasagi5, Wataru Matsumura1, Yoshihiro Maegaki6, Eiji Nanba7. 1. Division of Child Neurology, Institute of Neurological Sciences, Tottori University Faculty of Medicine, Yonago 683-8504, Japan; †Division of Clinical Genetics, Tottori University Hospital, Yonago 683-8504, Japan. 2. ‡Division of Functional Genomics, Research Center for Bioscience and Technology, Tottori University, Yonago 683-8503, Japan. 3. §Division of Technical Department, Tottori University, Yonago 683-8503, Japan. 4. †Division of Clinical Genetics, Tottori University Hospital, Yonago 683-8504, Japan; ‖Center for Promoting Next-Generation Highly Advanced Medicine, Tottori University Hospital, Yonago 683-8504, Japan. 5. †Division of Clinical Genetics, Tottori University Hospital, Yonago 683-8504, Japan; ¶Department of Fundamental Nursing, School of Health Science, Tottori University Faculty of Medicine, Yonago 683-8503, Japan. 6. Division of Child Neurology, Institute of Neurological Sciences, Tottori University Faculty of Medicine, Yonago 683-8504, Japan. 7. †Division of Clinical Genetics, Tottori University Hospital, Yonago 683-8504, Japan; ‡Division of Functional Genomics, Research Center for Bioscience and Technology, Tottori University, Yonago 683-8503, Japan; ‖Center for Promoting Next-Generation Highly Advanced Medicine, Tottori University Hospital, Yonago 683-8504, Japan.
Abstract
BACKGROUND: Genetic diagnoses provide beneficial information to patients and families. However, traditional genetic diagnoses are often difficult even for experienced clinicians and require recognition of characteristic patterns of signs or symptoms to guide targeted genetic testing for the confirmation of diagnoses. Next-generation sequencing (NGS) is a powerful genetic diagnostic tool. However, whole-genome and whole-exome sequencing (WES) are expensive, and the interpretation of results is difficult. Hence, target gene capture sequencing of gene panels has recently been applied to genetic diagnoses. Herein, we demonstrate that targeted sequencing approaches using gene panel testing are highly efficient for the diagnosis of Mendelian disorders. METHODS: NGS using TruSight one gene panel was performed in 17 families and 20 patients, and we developed a bioinformatic pipeline at our institution for detecting mutations. RESULTS: We detected causative mutations in 6 of 17 (35%) families. In particular, 11 (65%) families had syndromic diagnosis and 6 (35%) had no syndromic diagnosis before NGS testing. The number of positive diagnoses was 5 of 11 (45%) in the syndromic group and were 1 of 6 (17%) among patients of the no syndromic diagnosis group. CONCLUSION: Diagnostic yields in the present study were higher than in previous reports of genetic and chromosomal tests and WES. The present comprehensive gene-targeted panel test is a powerful diagnostic tool for Mendelian disorders.
BACKGROUND: Genetic diagnoses provide beneficial information to patients and families. However, traditional genetic diagnoses are often difficult even for experienced clinicians and require recognition of characteristic patterns of signs or symptoms to guide targeted genetic testing for the confirmation of diagnoses. Next-generation sequencing (NGS) is a powerful genetic diagnostic tool. However, whole-genome and whole-exome sequencing (WES) are expensive, and the interpretation of results is difficult. Hence, target gene capture sequencing of gene panels has recently been applied to genetic diagnoses. Herein, we demonstrate that targeted sequencing approaches using gene panel testing are highly efficient for the diagnosis of Mendelian disorders. METHODS: NGS using TruSight one gene panel was performed in 17 families and 20 patients, and we developed a bioinformatic pipeline at our institution for detecting mutations. RESULTS: We detected causative mutations in 6 of 17 (35%) families. In particular, 11 (65%) families had syndromic diagnosis and 6 (35%) had no syndromic diagnosis before NGS testing. The number of positive diagnoses was 5 of 11 (45%) in the syndromic group and were 1 of 6 (17%) among patients of the no syndromic diagnosis group. CONCLUSION: Diagnostic yields in the present study were higher than in previous reports of genetic and chromosomal tests and WES. The present comprehensive gene-targeted panel test is a powerful diagnostic tool for Mendelian disorders.
Entities:
Keywords:
candidate gene analyses; diagnosis high-throughput DNA sequencing
Authors: R van Minkelen; Y van Bever; J N R Kromosoeto; C J Withagen-Hermans; A Nieuwlaat; D J J Halley; A M W van den Ouweland Journal: Clin Genet Date: 2013-06-25 Impact factor: 4.438
Authors: Yaping Yang; Donna M Muzny; Fan Xia; Zhiyv Niu; Richard Person; Yan Ding; Patricia Ward; Alicia Braxton; Min Wang; Christian Buhay; Narayanan Veeraraghavan; Alicia Hawes; Theodore Chiang; Magalie Leduc; Joke Beuten; Jing Zhang; Weimin He; Jennifer Scull; Alecia Willis; Megan Landsverk; William J Craigen; Mir Reza Bekheirnia; Asbjorg Stray-Pedersen; Pengfei Liu; Shu Wen; Wendy Alcaraz; Hong Cui; Magdalena Walkiewicz; Jeffrey Reid; Matthew Bainbridge; Ankita Patel; Eric Boerwinkle; Arthur L Beaudet; James R Lupski; Sharon E Plon; Richard A Gibbs; Christine M Eng Journal: JAMA Date: 2014-11-12 Impact factor: 56.272
Authors: G A Bellus; I McIntosh; E A Smith; A S Aylsworth; I Kaitila; W A Horton; G A Greenhaw; J T Hecht; C A Francomano Journal: Nat Genet Date: 1995-07 Impact factor: 38.330